Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Biol Psychiatry. 2010 Jun 8;68(3):256–264. doi: 10.1016/j.biopsych.2010.04.016

Figure 3.

Figure 3

PPARα blockade increases efficacy of nAChR agonists. (A) Under voltage-clamp mode, MK886 effect on dopamine neuron in presence (grey) or absence (black) of sodium-orthovanadate (OVN). (B) Under current-clamp mode, effects of enhanced endogenous ACh levels acting at nAChRs (neostigmine+atropine) in presence or absence of MK886 (0.3 µM). (C) Current-clamp recording of a dopamine neuron (left panel) showing enhanced nicotine response in presence of MK886 (0.3 µM). Dose-response curves depicting averaged effects of nicotine (right panel) on dopamine neurons in presence or absence of MK886. Numbers above bars indicate n values. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.005.